News

2017.12.13

OMR Inc. has executed a Joint Research Agreement with Mitsubishi Tanabe Pharma on therapeutic antibodies for neurodegenerative diseases treatment including ALS.

Order-made Medical Research Inc. (President: Yasufumi Murakami, HQs: Kashiwa City, Chiba, hereinafter referred to as “OMR”), Mitsubishi Tanabe Pharma Corporation (President: Masayuki Mitsuya, HQs: Osaka City, hereinafter referred to as "Mitsubishi Tanabe Pharma" ), and Trans Chromosomics, Inc. (President: Mitsuo Oshimura, HQs: Yonago, Tottori, hereinafter referred to as "TC") are pleased announce that three of companies executed a Joint Research Agreement on on therapeutic antibodies for neurodegenerative diseases treatment including amyotrophic lateral sclerosis (ALS) in November, 2017.

OMR is working on R&D for therapeutic antibodies against target molecules that were difficult to discover using unique antibody engineering technology " LIMAXYS TM ". TC possesses fully human antibody-producing animals using its own artificial chromosome technology and cell evaluation method concerning neurodegenerative diseases. Mitsubishi Tanabe Pharma is conducting edaravone (trade name: Radicat (Japan), Radicava (USA)), which has been used as a therapeutic agent in the acute phase of cerebral infarction, in Japan in June 2015, and additionally obtained approval for efficacy/effect as " Suppression of the progression of functional disorder of Amyotrophic Lateral Sclerosis ", and then FDA approved ALS as an indication in the United States in May 2017.

Please refer to this press release released by Mitsubishi Tanabe Pharma.

https://www.mt-pharma.co.jp/shared/show.php?url=../release/nr/2017/MTPC171213.html